Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adherence to Artemisinin-Based Combination Therapy (ACT) for the Treatment of Malaria in Sierra Leone
Brief Summary: The aim of this study is to address this gap in knowledge by measuring the level of patient adherence to co-formulated amodiaquine and artesunate (AQ-AS) compared to artemether-lumefantrine (AL) under routine conditions in Sierra Leone and explore the key factors that influence adherence. This will be addressed through a mixed methods study that will provide not only a measurement of adherence ACTs and malaria test results, but will also provide contextual information in order to better understand factors that affect adherence. Data will be collected through a series of interviews with health workers and parents/caregivers and through observations of patient-provider consultations.

The first stage of the study begins with semi-structured interviews and observations of patients/caretakers' consultations with health workers and will look at how health workers diagnose and treat malaria. This will be followed by short exit interviews at the health facility with caregivers to assess patient satisfaction with services, as well as to test the consistency between the data obtained through structured observations and the exit interviews.

Follow-up surveys at the homes of patients will be used to measure and compare the adherence of participants to two different ACTs (AQAS and AL) formulations and potential factors that affect adherence. Additionally, data will be collected using in-depth interviews to collect supplementary information in order to discover, in more detail, factors that may affect behavioral choices and/or attitudes with regard to adherence.


Options:
A: Arm Label: Eurartesim dispersible oral tablets; Type: EXPERIMENTAL; Interventions: Drug: Eurartesim dispersible oral tablet | Arm Label: Eurartesim film coated tablet; Type: ACTIVE_COMPARATOR; Interventions: Drug: eurartesim film coated tablet | Intervention Type: DRUG; Name: Eurartesim dispersible oral tablet; Assigned to Arm(s): Eurartesim dispersible oral tablets | Intervention Type: DRUG; Name: eurartesim film coated tablet; Assigned to Arm(s): Eurartesim film coated tablet
B: Arm Label: Pyronaridine-artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-artesunate | Arm Label: Artemether-lumefantrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artemether-lumefantrine combination | Intervention Type: DRUG; Name: Pyronaridine-artesunate; Assigned to Arm(s): Pyronaridine-artesunate | Intervention Type: DRUG; Name: Artemether-lumefantrine combination; Assigned to Arm(s): Artemether-lumefantrine
C: Arm Label: co-formulated Amodiaquine-Artesunate; Type: ACTIVE_COMPARATOR; Interventions: Drug: amodiaquine-artesunate (AQAS) fixed-dose | Arm Label: artemether-lumefantrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artemether-lumefantrine combination (AL) dispersable | Intervention Type: DRUG; Name: amodiaquine-artesunate (AQAS) fixed-dose; Assigned to Arm(s): co-formulated Amodiaquine-Artesunate | Intervention Type: DRUG; Name: Artemether-lumefantrine combination (AL) dispersable; Assigned to Arm(s): artemether-lumefantrine
D: Intervention Type: DRUG; Name: Artemether-lumefantrine; Assigned to Arm(s): N/A

Answer: C